Načítá se...
Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease
BACKGROUND: Vesicular monoamine transporter 2 (VMAT2) inhibitors can improve hyperkinetic movements, and are effective treatment options for chorea of Huntington disease (HD). Tetrabenazine was assessed for treating chorea in the TETRA-HD trial, and while efficacious, there are tolerability concerns...
Uloženo v:
| Vydáno v: | J Clin Mov Disord |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5331691/ https://ncbi.nlm.nih.gov/pubmed/28265459 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40734-017-0051-5 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|